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Abstract
Background: CD95 is a death receptor controlling not only apoptotic pathways but also activating mechanisms 
promoting tumor growth. During the acquisition of chemoresistance to oxaliplatin there is a progressive loss of CD95 
expression in colon cancer cells and a decreased ability of this receptor to induce cell death. The aim of this study was 
to characterize some key cellular responses controlled by CD95 signaling in oxaliplatin-resistant colon cancer cells.
Results: We show that CD95 triggering results in an increased metastatic ability in resistant cells. Moreover, oxaliplatin 
treatment itself stimulates cell migration and decreases cell adhesion through CD95 activation, since CD95 expression 
inhibition by siRNA blocks the promigratory effects of oxaliplatin. These promigratory effects are related to the 
epithelia-to-mesenchymal transition (EMT) phenomenon, as evidenced by the up-regulation of some transcription 
factors and mesenchymal markers both in vitro and in vivo.
Conclusions: We conclude that oxaliplatin treatment in cells that have acquired resistance to oxaliplatin-induced 
apoptosis results in tumor-promoting effects through the activation of CD95 signaling and by inducing EMT, all these 
events jointly contributing to a metastatic phenotype.
Background
CD95 (APO-1/Fas), a 48 kDa membrane protein belong-
ing to the TNF receptor superfamily, activates caspase-
dependent apoptosis in susceptible cells when is activated
by its natural ligand (CD95L). There are two different cell
types that use distinct CD95 apoptosis signaling path-
ways. After CD95 triggering, type I cells activate caspase-
8 at the death-inducing signaling complex (DISC) fol-
lowed by activation of caspase-3. Apoptosis induction in
these cells is not sensitive to mitochondria pathway inhi-
bition. However, in type II cells DISC formation is
strongly reduced and the activation of caspase-8 and cas-
pase-3 is produced downstream of mitochondrial events.
Thus, inhibition of the mitochondrial role in these cells
by overexpression of Bcl-2 or Bcl-xL blocks apoptosis
[1,2]. This classification is related to cell phenotype, since
type I cells correspond to mesenchymal tumors and type
II cells display a more epithelial phenotype [3].
Many cancer cells acquire survival advantage during
tumor progression by decreasing its sensitivity to CD95-
induced apoptosis [4,5]. Some mechanisms affecting
CD95 sensitivity include downregulation of CD95 pro-
tein expression [6], blocking of the active receptor site by
the soluble form of CD95 ligand (sCD95L) [7], blocking
of the interaction of CD95L with CD95 by the soluble
decoy receptor 3 [8] and altered survival signaling path-
ways, among others (reviewed in [9]). In fact, this loss of
CD95-responsiveness seems to be produced in parallel to
tumor progression towards a more metastatic phenotype
[5,10]. In colon cancer cell lines the functional elimina-
tion of CD95-responsive cells select for the outgrowth of
different metastatic subpopulations, and cells isolated
from the metastatic sites of xenografts tumors are resis-
tant to CD95-induced apoptosis [10]. In agreement with
this observation, there is almost a complete loss of detect-
able CD95 expression in metastatic lesions of colon can-
cer patients compared with the primary lesions [11].
However, this loss of sensitivity to CD95-induced apop-
tosis could reflect a change in its functionality since some
of these CD95 apoptosis-resistant cells respond to CD95
activation with increased motility and invasiveness [5,12],
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contributing to the development of the metastatic pheno-
type. In fact, it has been recently demonstrated that
human and mouse colon cancer cells metastasize to the
liver by using CD95 signaling [13]. Therefore, CD95
receptor can also exert roles beyond apoptosis and favor
tumor-promoting effects in CD95 apoptosis-resistant
tumor cells [12]. The selective pressure exerted by oxalip-
latin treatment also selects for apoptosis-resistant cells
with alterations in CD95-regulated signaling pathways
and decreased CD95 expression. In these oxaliplatin-
resistant cells, activation of CD95 induces the phospho-
rylation of p42/44 MAPK and p38 MAPK, suggesting
that changes in the receptor functionality are related to
the acquisition of resistance to oxaliplatin [14]. In fact,
induction of cell death by some cytotoxic drugs seems to
be cell-type specific and to depend on the presence of an
intact CD95 system [15]. For example, the apoptotic-
effects of some cytotoxic agents such as doxorubicin and
oxaliplatin are mediated by upregulation of CD95 and
CD95L expression, and by activation of the apoptotic sig-
naling in the neighboring cells [7]. Therefore, tumor pro-
gression or mechanisms of selective pressure that alter
CD95 status would subsequently affect chemotherapy
sensibility and cell behavior.
We previously reported that, in a way similar to what
happens during tumor progression, acquisition of
chemoresistance also selects for cells in which the func-
tional activation of CD95 does not induced apoptosis but
instead activates MAPK proteins and the NF-κB pathway
[14]. Since oxaliplatin treatment is known to increase
CD95 expression in both sensitive and resistant cell lines
[14] the aim of the present study was to ascertain if oxali-
platin up-regulation of CD95 expression could contribute
to the acquisition of a more aggressive behavior. Briefly,
we show that drug treatment stimulates migration and
decreases adhesion by means of CD95 activation in cells
that have acquired resistance to oxaliplatin-induced
d e a t h .  W e  a l s o  r e p o r t  t h a t  o x a l i p l a t i n - r e s i s t a n t  c e l l s
undergo EMT, as evidenced by the expression profile of
several markers, and that oxaliplatin treatment also con-
tributes to the acquisition of a more mesenchymal phe-
notype in the resistant cells and tumor xenografts. Finally,
we have found that CD95 triggering in chemoresistant
cells activates MAPK pathways and alters the expression
levels of certain cell cycle proteins with previously
described promigratory roles. We conclude that oxalipla-
tin treatment in cells that have acquired resistance to
oxaliplatin-induced apoptosis could result in tumor-pro-
moting effects by activation of CD95 promigratory sig-
naling and by inducing EMT, which jointly contribute to
the acquisition of a more metastatic phenotype.
Results and Discussion
Oxaliplatin induces cell migration by activation of CD95 
receptor in resistant cells
Some colon cancer cell lines resistant to CD95-induced
apoptosis respond to CD95 activation with increased
motility and invasiveness. Taking into account that oxali-
platin treatment increases CD95 expression in both sen-
sitive and resistant cell lines, we aimed to determine if
oxaliplatin stimulation of CD95 expression could exert a
pro-migratory effect. To address directly this question we
used a previously characterized model of acquired
chemoresistance based on the cell lines HT29 and
HCT116 p53-/- and their corresponding oxaliplatin-resis-
tant derived cell lines RHT29, and RHCT116 p53-/- [14].
To determine the effects of oxaliplatin and CD95 activa-
tion on cell migration we performed transwell migration
assays as described in the Material and Methods section.
As expected, FBS stimulation induced a significant
increase in basal cell migration both in HT29 and RHT29
cells (1,7 and 1,9-fold induction, respectively) and in the
HCT116 p53-/- and RHCT116 p53-/- (1,5-fold induction
in both cell lines) (Figure 1A). Pretreatment of cells with
oxaliplatin results in a higher migration capacity in
RHT29 and RHCT116 p53-/- cells (1,3-fold induction in
both cases). Interestingly, a strong stimulation of cell
migration was observed again in RHT29 and RHCT116
p53-/- cell lines (3-fold and 1,5-fold induction, respec-
tively) after agonistic CH11 antibody treatment (Figure
1A). This effect was not significantly enhanced when cells
were pre-treated with oxaliplatin, probably due to the
promigratory effects exerted by CH11 alone that masked
the increase induced by oxaliplatin. On the other hand,
neither HT29 nor HCT116 p53-/- cells were affected by
CH11-induced CD95 activation or drug pretreatment
(Figure 1A), indicating that the activation of CD95 only
induces cell migration in the oxaliplatin-resistant cell
lines.
T o  b e t t e r  u n d e r s t a n d  t h e  c o n t r i b u t i o n  o f  C D 9 5  i n
oxaliplatin-induced cell migration CD95 expression was
abrogated by siRNA under the same experimental condi-
tions (Figure 1A and Additional file 1: Fig S1). The inhibi-
tion of CD95 expression did not affect basal migration
rate, but completely abrogated oxaliplatin-induced
migration in the RHT29 and RHCT116 p53-/- cell lines,
confirming that the effects of oxaliplatin pretreatment in
cell migration are mediated by the activation of CD95
receptor. Similar results were obtained when the cells
were treated with the CD95-blocking antibody DX2
(Additional file 2: Fig S2). Finally, cell growth curves were
performed under the same experimental conditions and
no differences in cell proliferation rates were found (dataAmetller et al. Molecular Cancer 2010, 9:161
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not shown), ruling out any possible contribution of differ-
ences in proliferation rates among cell lines to the migra-
tion assay results.
To determine if these effects on cell migration were
accompanied by changes on cell adhesion we determined
the capability of the various cell lines to adhere to
fibronectin-coated surfaces. Oxaliplatin pretreatment
significantly increased cell adhesion in HT29 cells but not
in RHT29 cells (Figure 1B). Interestingly, however, CD95
stimulation by CH11 induced a significant decrease on
basal adhesion ability in the RHT29 cell line and this was
also evident even under oxaliplatin-pretreatment. CD95
inhibition by siRNA slightly affected RHT29 adhesion
ability and significantly increased basal HT29 adhesion
under oxaliplatin-pretreatment. Similar results were
obtained when CD95 activation was blocked with DX2
antibody (Additional file 2: Fig S2). Finally, CD95 activa-
tion by CH11 also decreased cell adhesion in the
RHCT116 p53-/- cell line, while remaining unaltered by
any treatment in HCT116 p53-/- cells (Figure 1B).
Taken together, these results indicate that oxaliplatin
treatment stimulated cell migration in oxalipaltin-resis-
tant cell lines by activating CD95 receptor, since forced
activation of CD95 by an agonistic antibody strongly
increased migration and decreased cell adhesion while
CD95 silencing and inhibition efficiently abrogated oxali-
platin effects.
Treatment with oxaliplatin induces the phosphorylation of 
p42/44 MAPK and p38 MAPK proteins
Stimulation of motility and invasiveness by CD95 is
mediated by the activation of different signaling pathways
including caspase-8, NF-κB and phospho-p42/44 MAPK
[12]. Moreover, oxaliplatin induces the activation of p38
MAPK [16] and NF-κB [14,17] in several cell lines. The
p38 MAPK has been described as a classical tumor sup-
pressor [18,19], but p38 MAPK seems to play also other
roles, such as increasing cell survival as a cellular defense
mechanism to overcome the effects of cytotoxic drugs
and also promoting cellular migration [20]. In addition,
oxaliplatin increases NF-κB signaling in both HT29 and
Figure 1 Effects of oxaliplatin and CD95 activation on cell migration and adhesion in oxaliplatin-resistant cells. A) To determine the effects 
of oxaliplatin or CD95 triggering on cell migration different sensitive (HT29 and HCT116 p53-/-) and resistant (RHT29 and RHCT116 p53-/-) cell lines were 
treated with oxaliplatin (10 μM for the HT29 and RHT29 and 5 μM for the HCT116 p53-/- and RHTC116 p53-/-) or/and the CD95 agonistic antibody CH11 
(150 ng/ml) for 24 hours, and their migratory ability was assessed in transwell assays. The contribution of CD95 activation to oxaliplatin-induced cell 
migration was determined by inhibiting CD95 expression with siRNA. B) The effects of oxaliplatin or CD95 triggering on the adhesion ability of the 
different cell lines or the contribution of CD95 activation to oxaliplatin-induced cell adhesion were determined under the same experimental condi-
tions on fibronectin coated plates. The experiments were performed in triplicate and results represent the mean ± SEM. Values that are significantly 
different from control group by ANOVA's analysis are indicated by *p < 0.05, **p < 0.01, and those different from the oxaliplatin-treated group are 
indicated by •p < 0.05. OXA: oxaliplatin, FBS: Fetal bovine serum.Ametller et al. Molecular Cancer 2010, 9:161
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RHT29 cells but only the RHT29 cell line has dependence
on the NF-κB pathway for survival [14]. For these reasons
we next decided to determine if oxaliplatin treatment dif-
ferentially contributes to the activation of p42/44 MAPK,
p38 MAPK and the p65 subunit of NF-κB in the HT29
and RHT29 cell lines. We also investigated the signaling
pathways activated by CD95 under oxaliplatin treatment.
HT29 and RHT29 cells were treated with oxaliplatin 10
μM for 48 hours and with 150 ng/ml of the CD95 agonis-
tic antibody CH11 for 24 hours. As previously observed,
oxaliplatin treatment activated p42/44 MAPK (Figure
2A) and p38 MAPK (Figure 2B). Activation of CD95 by
CH11 increased the levels of p42/44 MAPK (Figure 2A)
and p38 MAPK (Figure 2B) in the oxaliplatin-resistant
cell line, but not in the sensible one. Moreover, oxaliplatin
treatment slightly increased the effects of the agonistic
antibody CH11 (Figure 2A and 2B). The inhibition of
extracellular metalloproteinases, which decreased CD95
expression by receptor cleavage at the plasma membrane,
also enhanced the effects of CH11 (data not shown), con-
firming the involvement of CD95 in the activation of
MAPK pathways in the RHT29 cell line. Total amounts of
active NF-κB were not significantly increased by CD95
activation in any of the cell lines analyzed (Figure 2C).
These results suggest that in cells that have acquired
resistance to oxaliplatin CD95 triggering stimulates
MAPK pathways known to contribute to the motility and
invasiveness of these cells.
Oxaliplatin treatment differentially affects cell cycle and 
apoptosis-related proteins
NF-κB is constitutively expressed in a wide range of
tumor cells, where it commonly promotes cell prolifera-
tion and resistance to apoptosis induced by genotoxic
agents [17,21]. After exposure to oxaliplatin cells can suf-
fer an arrest in G1 or G2/M followed by an S-phase delay
[22-24]. Taking into account that cells respond to oxalipl-
atin by increasing NF-κB activity [14], which controls
cyclin D1 expression [25], we also decided to analyze if
oxaliplatin treatment was differentially affecting cell cycle
profiles, proteins levels and apoptosis related proteins.
HT29 and RHT29 cell lines were treated with oxalipla-
tin for 24 and 48 hours and protein expression was deter-
mined by Western blot analysis. Basal levels of cyclin D1
were higher in the RHT29 cells compared to the HT29
cells (Figure 3A). Oxaliplatin treatment induced opposing
effects in these cell lines. Whereas a significant increase
in cyclin D1 expression was found in the RHT29 cell line,
parental cells showed lower cyclin D1 protein expression
after oxaliplatin. Interestingly, the upregulation of cyclin
D 1  e x p r e s s i o n  i n  t h e  R H T 2 9  c e l l s  a g r e e s  w i t h  t h e
increase in active NF-κB previously observed [14] and
might be supporting their increased migratory ability
described in the present paper (Figure 1A). Basal expres-
sion of p27 was slightly lower in the RHT29 cell line,
being not significantly affected by oxaliplatin treatment
in any cell line.
Basal expression of CDK2 and CDK4 were significantly
higher in the RHT29 cell line and oxaliplatin treatment
increased CDK2 (transiently) and CDK4 expression (Fig-
ure 3A). CDK2 levels were found increased in HT29 cells
after 48 h oxaliplatin treatment and a slight decrease was
observed in CDK4 levels after 24 h of treatment in the
HT29 cell line. Therefore, the RHT29 cell line showed
higher levels of proteins related to proliferation and cell
cycle progression and lower levels of the cell cycle inhibi-
tor p27, all these changes accounting for its acquired
resistance to oxaliplatin.
Next, we analyzed by flow cytometry the effects of 48
hours of oxaliplatin exposure (10 μM) in the cell cycle dis-
tribution of both cell lines. The percentage of cells in the
sub-G1 phase was significantly higher in the HT29 cell
line compared to the RHT29 cell line, as expected (Figure
3B). In this case no arrest in the G1 phase was detected,
probably because the dose and the time analyzed induced
the majority of cells to undergo cell death. However,
oxaliplatin induced an S-phase cell accumulation in the
RHT29 cell line, suggesting that the drug could be pro-
moting G1/S transition by upregulating cyclin D1, CDK4
and CDK2 but making it difficult to complete the S-
phase, thus exerting a cytostatic rather than a cytotoxic
effect on these oxaliplatin-resistant cells (Figure 3B).
We also determined the expression levels of active cas-
pase-8, Bcl-2 and Bax proteins in HT29 and RHT29. We
found that in the resistant cell line RHT29 oxaliplatin was
less effective in inducing the activation of caspase-8 (Fig-
ure 4A and 4B). Furthermore, we also found increased
basal Bcl2 levels and an increased Bcl2/Bax ratio in the
oxaliplatin-treated RHT29 cells (Figure 4C-4E) further
indicating that in this resistant cell line, the upregulation
of survival pathways is contributing to the resistance to
oxaliplatin-induced apoptosis.
Acquisition of resistance to oxaliplatin induces EMT and 
confers a more motile phenotype
The differential cell migratory responses of sensitive and
resistant colon cancer cells to oxaliplatin led us to con-
sider the possibility that resistant cells have undergone
epithelial-to-mesenchymal transition (EMT), as
described by others [26] and thus their motility capacity
could result concomitantly affected. Gene expression of
epithelial and mesenchymal markers and transcription
factors related to the EMT reprogramming was studied
under basal and oxaliplatin-treated conditions to deter-
mine if they were differentially expressed in HT29 and
RHT29 cells. Figures 5 A1 and 5 A2 show the differential
basal expression of the EMT markers between HT29 and
RHT29 cells. In spite of the lack of any significantAmetller et al. Molecular Cancer 2010, 9:161
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decrease in the epithelial markers E-cadherin, α-catenin
or γ-catenin, basal expression of the transcription factors
Twist and Snail and the mesenchymal markers fibronec-
tin and vimentin were significantly higher in the oxalipla-
tin-resistant cell line RHT29 (Figures 5 A1 and 5 A2),
suggesting that parallel to the acquisition of chemoresis-
tance there is a change in the expression profile of these
markers towards a more mesenchymal phenotype [26].
Figures 5 B1 and 5 B2 show the differential induction of
the same markers under oxaliplatin treatment in both cell
lines, expressed as fold-induction versus  basal levels.
Although oxaliplatin failed to induce cell migration in the
HT29 cell line, drug treatment up-regulated the expres-
sion of the transcription factors Twist, Snail and Slug,
Figure 2 Differential activation of MAPK pathways by CD95 in cells resistant to oxaliplatin-induced cell death. To determine the contribution 
of oxaliplatin-induced CD95 to the activation of A) p42/44 MAPK, B) p38 MAPK signaling pathways and to the activation of C) NF-κB (p65 NLS), cells 
were treated with oxaliplatin (10 μM), the CD95 agonistic antibody CH11 (150 ng/ml) or the combination of both for 48 hours, and the protein levels 
determined by Western blot.Ametller et al. Molecular Cancer 2010, 9:161
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decreased α-catenin expression and increased the mesen-
chymal markers fibronectin and vimentin (Figures 5 B1
and 5 B2). In the RHT29 cell line oxaliplatin seems to
enhance the mesenchymal phenotype increasing the
expression of some of the EMT markers such as Slug,
fibronectin and vimentin and decreasing α-catenin (Fig-
ures 5 B1 and 5 B2). In agreement with the stimulation of
the EMT process, oxaliplatin treatment (10 μM for 24
hours) induced the development of a more fibroblast-like,
spindle-cell morphology in both cell lines (Additional file
3: Fig S3).
We also determined the expression of E-cadherin by
immunofluorescence and confocal microscopy analysis
(Figure 5C). Interestingly, E-cadherin levels increased in
the plasma membrane of the HT29 cells treated with
oxaliplatin, in agreement with the slight increase on
mRNA levels observed by qPCR. This could be related to
the increased adhesion of the HT29 cells observed under
oxaliplatin treatment (Figure 1B). Instead, basal E-cad-
herin expression progressively decreased in oxaliplatin-
treated RHT29 cells (data not shown), being completely
abrogated after 30 minutes (Figure 5C).
Finally, in an attempt to explore if this EMT process
was also taking place in vivo, we analyzed the gene
expression of the same markers in xenograft tumors,
either treated with oxaliplatin or not, generated from the
HT29 and the RHT29 cell lines [14]. Interestingly, similar
changes in the basal gene expression pattern of the tran-
scription factors, epithelial and mesenchymal markers
related to the EMT process were observed in vivo
between sensitive and resistant tumors when compared
to the in vitro data (Figures 5 A1 and 5 A2 and Figure 6
A1 and 6 A2). Furthermore, oxaliplatin treated tumors
closely mimic the changes on the expression patterns
found in vitro (Figures 5 B1 and 5 B2 and Figure 6 B1 and
6 B2), further supporting the ability of oxaliplatin to
induce EMT.
Therefore, oxaliplatin resistance induces the acquisi-
tion of a mesenchymal phenotype as observed for the
RHT29 cell line and its xenograft tumor. Moreover, oxali-
Figure 3 Oxaliplatin regulation of cell cycle-related proteins in the HT29 and RHT29 cell lines. A) HT29 and RHT29 cell lines were treated with 
oxaliplatin 10 μM for 24 and 48 hours and the expression of the cell-cycle related proteins cyclin D1, p27, CDK2 and CDK4 determined by Western blot. 
Results shown are the mean ± SEM of the densitometric quantification three independent experiments. Values that are significantly different between 
groups by ANOVA's analysis are indicated by *p < 0.05, and those different between non-treated and treated groups are indicated by •p < 0.05, ••p < 
0.01, •••p < 0.001. B) Cell cycle studies: the distribution of the different phases of the cell cycle was determined in HT29 and RHT29 cells by flow cytom-
etry. CDK2: cyclin-dependent kinase 2, CDK4: cyclin-dependent kinase 4.Ametller et al. Molecular Cancer 2010, 9:161
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Page 7 of 12
platin treatment seems to induce gene reprogramming
and EMT in both sensitive and resistant cells in vitro and
in vivo that specifically confers a more motile phenotype
to resistant cells.
Conclusions
In this study we have used previously characterized cell
lines [14] as an in vitro model of acquired chemoresis-
tance. We took advantage of the differential CD95 func-
tionality displayed by these cell lines, as a result of the
acquired chemoresistance process, to investigate the
CD95-mediated cellular responses differentially regu-
lated in sensitive and oxaliplatin-resistant cells. We have
focused on the differential effects of oxaliplatin in the
activation of MAPK pathways, migration and adhesion
and the contribution of CD95 to all these processes, dem-
onstrating that direct or oxaliplatin-induced CD95 acti-
vation in chemoresistant cells has tumor-promoting
effects. Finally, we have demonstrated that oxaliplatin-
treated cells and tumors initiate but do not complete an
EMT-like program and that chronic exposure to oxalipla-
tin renders them more prone to complete EMT, as they
had already initiated EMT gene reprogramming during
the acquisition of resistance to oxaliplatin. The diverse
CD95-mediated oxaliplatin responses described can ulti-
mately be responsible for the different cellular behavior
observed between sensitive and resistant cells when
exposed to oxaliplatin.
The general assumption that the CD95 receptor works
as a death receptor has changed over the last years with
the discovery that CD95 can mediate apoptosis-indepen-
dent processes including proliferation, migration, angio-
genesis and inflammation [12,27-29]. These changes in
CD95 functionality seem to be related with membrane
microdomain location, receptor internalization and
endosomal trafficking [30]. However, whether the type of
CD95 signaling is an intrinsic trait or a mechanism that
can be acquired by changes in cell phenotype has never
been addressed before. Moreover, specific tumor-pro-
moting effects of CD95 stimulation in chemoresistant
cells have not been reported. In cancer, the responsive-
ness to CD95 activation has been classified by Scaffidi et
al [2] as dependent (type II cells) or independent (type I
cells) from mitochondria. On the other hand, Algeciras-
Schimnich et al [3] classified type I cell lines as those cor-
responding to a mesenchymal phenotype whereas the
type II cell lines preferentially express epithelium-like
markers.
The results from Algeciras-Schimnich et al [3] suggest
that type I and II tumor cells represent different stages of
carcinogenesis that resemble the EMT process. In fact,
we have observed in our model of acquired chemoresis-
Figure 4 Oxaliplatin regulation of apoptosis-related proteins in the HT29 and RHT29 cell lines. HT29 and RHT29 cell lines were treated with 
oxaliplatin 10 μM for 24 and 48 hours and the expression of the A) active caspase 8 and C) Bcl-2 and Bax were determined by Western blot. B) Densi-
tometry of active caspase 8. D-E) Ratio between Bcl-2 and Bax for the HT29 and RHT29 cell lines based on the densitometry quantification.Ametller et al. Molecular Cancer 2010, 9:161
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Figure 5 Analysis of EMT markers and E-cadherin expression on HT29 and RHT29 cells. (A1) Differential basal expression of some transcription 
factors related to the EMT process and (A2) markers of epithelial and mesenchymal phenotype were determined in the HT29 and RHT29 cell lines by 
qPCR. (B1) The effects of oxaliplatin in the gene expression of those transcription factors and (B2) EMT markers were also analyzed in cells treated with 
oxaliplatin 10 μM for 48 hours and in this case the results are shown as fold induction versus non-treated cells. Results represent the mean ± SEM of 
triplicates. Values that are significantly different between (A) groups or between (B) non-treated and treated groups by ANOVA's analysis are indicated 
by *p < 0.05, **p < 0.01, ***p < 0.001. C) HT29 and RHT29 cells were treated with oxaliplatin 10 μM for 48 hours and E-cadherin expression was detected 
by immunofluorescence and confocal microscope analysis. Scale bar is 50 μm.Ametller et al. Molecular Cancer 2010, 9:161
http://www.molecular-cancer.com/content/9/1/161
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tance that the changes in CD95 signaling are accompa-
nied by EMT, suggesting that CD95 functionality can
switch as a consequence of changes in cell phenotype.
Moreover, in these chemoresistant cells displaying a mes-
enchymal phenotype, CD95 signaling strongly induces
cell migration and decreases cell adhesion in agreement
with the proposed tumor-promoting effects of CD95 in
some cell types.
The fact that during the acquisition of chemoresistance
CD95 can switch its functionality could have relevant
clinical implications. Chemotherapy acts as a selective
pressure selecting resistant clones. If chemotherapy fails
to eliminate the bulk of the tumor, the resulting resistant
clones will sustain the regrowth of the tumor. As demon-
strated in this work, these clones selected under chemo-
therapy show a mesenchymal phenotype and express a
CD95 receptor with a non-apoptotic function. Moreover,
the continuous exposure of these cells to oxaliplatin will
allow the activation of CD95 and the stimulation of
tumor-promoting pathways as well as cell migration.
Therefore, oxaliplatin treatment of cells resistant to oxali-
platin-induced cell death could ultimately have tumor
promoting effects by the upregulation and activation of
prosurvival and promigratory CD95-controlled path-
ways. Then, more research efforts are needed to better
understand how the acquisition of chemotherapy is pro-
duced, the time point at which tumor cells have acquired
resistance to chemotherapy and consistently when the
treatment could have detrimental effects.
Materials and methods
Cell lines and reagents
Human colon carcinoma cell line HT29 was purchased
from American Type Culture Collection (Rockville, MD).
Figure 6 Analysis of EMT markers on HT29 and RHT29 xenografts. (A1) Differential basal expression of some transcription factors related to the 
EMT process and (A2) markers of epithelial and mesenchymal phenotype were determined by qPCR in tumor xenografts derived from the HT29 and 
RHT29 cell lines. (B1) The effects of oxaliplatin in the gene expression of those transcription factors and (B2) EMT markers were also analyzed in xeno-
grafted tumors treated with oxaliplatin (i.p. 10 mg/kg) once per week during 27 days and in this case the results are shown as fold induction versus 
non-treated tumors. Results represent the mean ± SEM for 6 xenografts per group. Values that are significantly different between (A) groups or be-
tween (B) non-treated and treated groups by ANOVA's analysis are indicated by *p < 0.05, **p < 0.01, ***p < 0.001.Ametller et al. Molecular Cancer 2010, 9:161
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The HCT116 p53-/-  was generously given by Dr.
Vogelstein. The oxaliplatin-resistant cell lines were devel-
o p e d  b y  r e p e a t e d  e x p o s u r e  o f  t h e  p a r e n t a l  c e l l s  t o
increasing concentrations of oxaliplatin as we previously
described [14]. Experiments were performed with the
resistant population obtained from this process instead of
using clones to better mimic the normal process by which
a patient develops chemoresistance and to maintain some
degree of tumor heterogeneity. All cell lines were cul-
tured in McCoy's Medium supplemented with 10% heat
inactivated fetal bovine serum (FBS), antibiotics (Gibco,
Invitrogen). The cultures were incubated at 37°C in a
humidified 5% CO2 atmosphere and the cells were serum
starved overnight before experiments.
Antibodies used were mouse monoclonal anti-Fas
(clone DX2) from Pharmingen; mouse monoclonal anti-
Fas (clone CH11) from Upstate Biotechnology; mouse
monoclonal anti-NF-κB (NLS epitope) from Chemicon,
rabbit polyclonal antibodies against phospho-p42/44
MAPK, p42/44 MAPK, phospho-p38 MAPK and p38
MAPK, were from Cell Signaling Technology, mouse
monoclonal anti-caspase-8 from Calbiochem, mouse
monoclonal anti-Bcl2, rabbit monoclonal anti-Bax,
mouse monoclonal anti-cyclin D1, rabbit polyclonal anti-
bodies against CDK4, CDK2, and p27 were from Santa
Cruz Biotechnology and mouse monoclonal anti-tubulin
from Sigma. Oxaliplatin was from Sigma. All general
reagents were purchased from Sigma, Bio-Rad and Amer-
sham.
Western blot
The effects of oxaliplatin in regulatory cell cycle proteins
and pro and anti-apoptotic proteins were detected by
Western blot in cells treated with oxaliplatin 10 μM dur-
ing 24 and 48 hours. To study the contribution of CD95
to the induction of MAPK proteins and to the activation
of NF-κB the colon cancer cell lines were treated with
oxaliplatin (10 μM) for 48 hours and with CH-11 (150 ng/
ml) for 24 hours. Protein was extracted and analyzed by
Western blot as previously described [31] and tubulin
expression was used as endogenous control. Image cap-
ture was performed with a Luminiscent Image Analyzer
LAS-3000 (Fujifilm, Japan) and image analysis and densi-
tometric quantification by using the Image Reader soft-
ware (Fujifilm).
Transfection with antisense CD95
Silencing of CD95 was done by Stealth RNAi technology
from Invitrogen as previously described for other genes
[14], which provides three different chemical modified
oligonucleotides against three different regions of the RNA
target. The three probes used for the silencing of CD95
were: Probe 1, Cat#10620318, FASHSS100597: UGAC
AAUGUCCAAGACACAGCAGAA and Cat#10620319
FASHSS100597: UUCUGCUGUGUCUUGGACAUU-
GUCA; Probe 2, Cat#10620318 FASHSS100598: GGUU
CUUACGUCUGUUGCUAGAUUA and Cat#10620319
FASHSS100598: UAAUCUAGCAACAGACGUAAGA
ACC; Probe 3, Cat#10620318 FASHSS100599: GGGAU
UGGAAUUGAGGAAGACUGUU and Cat#10620319
FASHSS100599: AACAGUCUUCCUCAAUUCCAAUC
CC. Before silencing experiments, the protocol was
adjusted to ensure a minimum of 80% of RNA knock-
down assessed by qPCR.
Migration and adhesion
Migration assays were performed in transwell inserts
(with 8 μm pore size and UV-opaque membrane from
Becton Dickinson). The undersurface of transwells were
coated with 5 μg of human plasma fibronectin (SIGMA)
or 1% BSA (negative control) and blocked with of 2% FBS.
Cells previously treated with oxaliplatin oxaliplatin (10
μM for the HT29 and RHT29 and 5 μM for the HCT116
p53-/- and RHTC116 p53-/-), CH-11 (150 ng/ml) or or
DX2 (400 ng/ml) during 10 hours or silenced for CD95 by
siRNA for 48 hours were labeled with Calcein-AM 5 μM
(Invitrogen) for 30 min. Then, cells were resuspended in
100 μl of serum-free medium and the corresponding
treatment depending on the group (oxaliplatin, CH-11
and DX2), and 130 × 103 cells per transwell were seeded
and allowed to migrate for 14 hours at 37°C (time of every
treatment at the end of the experiment was 24 hours).
Medium containing a 10% of FBS was placed at the bot-
tom of the wells and used as chemoattractant. After the
14 hours of migration cells on the bottom of the transwell
were fluorimetrically detected by using the Biotek Spec-
traFluor plate reader, with 485 nm excitation and 530 nm
emission filters. The experiment was performed in tripli-
cate and fluorescence values were normalized versus the
non-treated non-stimulated control cells.
For the adhesion assay 24-well plates were coated with
fibronectin (50 μg/ml) or 1% BSA (negative control) at
37°C for 3 hours, and blocking of non-specific binding
sites was performed using 1% BSA during 30 minutes at
3 7 ° C.  Be f o r e  a s s a y s,  c e l l s  w e r e  t r e a t ed  w i t h  o x a l i p l a t i n
oxaliplatin (10 μM for the HT29 and RHT29 and 5 μM for
the HCT116 p53-/- and RHTC116 p53-/-), CH-11 (150 ng/
ml) or DX2 (400 ng/ml) depending on the experimental
group during 24 hours, or CD95 was silenced by siRNA.
Cells were fluorescence-labeled with calcein-AM and 4 ×
105 cells per well were left to adhered on the 24-well
coated plates for 2 hours at 37°C. Nonadherent cells were
removed by washing the wells with PBS and attached cells
were quantified by measuring the fluorescence emission
using the Biotek SpectraFluor plate reader, with 485 nm
excitation and 530 nm emission filters. Every experiment
was performed in triplicate.Ametller et al. Molecular Cancer 2010, 9:161
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Immunofluorescence Assay
For the detection of E-cadherin cells were seeded in cov-
erslips until subconfluence and treated with oxaliplatin
10 μM for 30 minutes. Then, cells were immunostained
as previously described [14] using the mouse primary
antibody against E-cadherin (Cell Signaling). Samples
were viewed using an inverted epifluorescence micro-
scope (Leica) and image assembly and processing were
performed using the Image Processing Leica Confocal
Software at the Microscopy Unit of the School of Medi-
cine of the University of Barcelona.
qPCR Analysis
Total RNA from tumor cells was isolated with Ultraspec
(Biotecx) according to the manufacturer's instructions.
Quantitative PCR analysis was done on the ABI PRISM
7900 Sequence Detector System (Applied Biosystems) as
previously described [14]. For determination of gene
expression Assay-on-demand (Applied Biosystems) was
used. Transcript levels were normalized to those of beta-
actin (Hs99999903_m1), which was used as endogenous
control. Each experiment and every determination were
done at least in triplicate, and the levels of gene expres-
sion were calculated using the ΔΔCt method.
Cell cycle
Cell cycle analysis was performed as described elsewhere
in cells treated with oxaliplatin 10 μM for 24 h. DNA con-
tent was determined on a FACscan flow cytometer using
FACSCalibur (BD Biosciences) and data processed by the
software CellQuest. Every experiment was performed in
triplicate.
In vivo experiments
In vivo experiments were performed with the HT29 and
the RHT29 colon cancer cell lines as previously described
[14]. All the experimental procedures with animals were
performed in accordance with the regulations of our
institution's Ethics Commission, following the guidelines
established by the government of Catalonia, Spain.
Statistical analysis
Statistical analysis of the results was performed by
ANOVA analysis. Statistical significance was considered
for p values less than 0.05.
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